Rapid Communication
Copyright ©2006 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jan 28, 2006; 12(4): 644-648
Published online Jan 28, 2006. doi: 10.3748/wjg.v12.i4.644
Role of transforming growth factor-beta1-smad signal transduction pathway in patients with hepatocellular carcinoma
Guo-Zhong Ji, Xue-Hao Wang, Lin Miao, Zheng Liu, Ping Zhang, Fa-Ming Zhang, Jian-Bing Yang
Guo-Zhong Ji, Lin Miao, Zheng Liu, Ping Zhang, Fa-Ming Zhang, Department of Gastroenterology, Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, Jiangsu Province, China
Xue-Hao Wang, Department of Hepatic Surgery, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China
Jian-Bing Yang, Qidong Liver Cancer Institute, Qidong 226200, Jiangsu Province, China
Supported by Natural Science Foundation of Jiangsu Province, No. BK2001168; Natural Science Foundation of Department of Education of Jiangsu Province, No. 02KJD320023; Science and Technology Innovation Foundation of Nanjing Medical University, No. CX2004004
Correspondence to: Dr. Guo-Zhong Ji, Department of Gastroenterology, Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011 , Jiangsu Province, China. jgzzl@163.com
Telephone: +86-25-83062888 Fax: +86-25-58509994
Received: July 15, 2005
Revised: July 28, 2005
Accepted: August 11, 2005
Published online: January 28, 2006
Abstract

AIM: To explore the role of transforming growth factor-beta1 (TGF-β1)-smad signal transduction pathway in patients with hepatocellular carcinoma.

METHODS: Thirty-six hepatocellular carcinoma specimens were obtained from Qidong Liver Cancer Institute and Department of Pathology of the Second Affiliated Hospital of Nanjing Medical University. All primary antibodies (polyclonal antibodies) to TGF-β1, type II Transforming growth factor-beta receptor (TβR-II), nuclear factor-kappaB (NF-κB), CD34, smad4 and smad7,secondary antibodies and immunohistochemical kit were purchased from Zhongshan Biotechnology Limited Company (Beijing, China). The expressions of TGF-β1, TβR-II, NF-κB, smad4 and smad7 proteins in 36 specimens of hepatocellular carcinoma (HCC) and its adjacent tissue were separately detected by immunohistochemistry to observe the relationship between TGF-β1 and TβR-II, between NF-κB and TGF-β1, between smad4 and smad7 and between TGF-β1 or TβR-IIand microvessel density (MVD). MVD was determined by labelling the vessel endothelial cells with CD34.

RESULTS: The expression of TGF-β1, smad7 and MVD was higher in HCC tissue than in adjacent HCC tissue (P<0.01, P <0.05, P <0.01 respectively). The expression of TβR-IIand smad4 was lower in HCC tissue than in its adjacent tissue (P <0.01, P <0.05 respectively). The expression of TGF-β1 protein and NF-κB protein was consistent in HCC tissue. The expression of TGF-β1 and MVD was also consistent in HCC tissue. The expression of TβR-IIwas negatively correlated with that of MVD in HCC tissue.

CONCLUSION: The expressions of TGF-β1, TβR-II, NF-κB, smad4 and smad7 in HCC tissue, which are major up and down stream factors of TGF-β1-smad signal transduction pathway , are abnormal. These factors are closely related with MVD and may play an important role in HCC angiogenesis. The inhibitory action of TGF-β1 is weakened in hepatic carcinoma cells because of abnormality of TGF-β1 receptors (such as TβR-II) and postreceptors (such as smad4 and smad7). NF-κB may cause activation and production of TGF-β1.

Keywords: TGF-β1, TβR-II, Smad4, Smad7, NF-κB, MVD, Hepatocellular carcinoma, Signal transduction